January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Hyunjin Yang, Director of Business Development at Ubix Therapeutics, will speak at the ACCESS ASIA BD Forum @ JPM 2026.
ACCESS ASIA, hosted by YAFO, builds on the success of ACCESS CHINA, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and strategic partners. Taking place on January 11, 2026, at the InterContinental San Francisco, the forum provides a global stage for Asian biotech companies to showcase their innovation, foster partnerships, and explore new business development opportunities. View more information at: https://biotochina.org/
About Ubix Therapeutics
Ubix Therapeutics is a clinical-stage biotechnology company focused on developing heterobifunctional degrader drugs, collectively known as Targeted Protein Degradation (TPD) therapeutics, with a primary emphasis on oncology. Its lead asset, UBX-303-1, is currently in a Phase 1a dose-escalation trial and has demonstrated good tolerability as well as early signs of efficacy at the first two dose levels.
About the speaker
Dr. Hyunjin Yang is the Director of Business Development at Ubix Therapeutics, leading global partnering and licensing strategies for the company’s degrader and DAC (Degrader–Antibody Conjugate) assets. With over 22 years of combined experience in industry and academia, she has a strong track record in partnership development, IPO preparation, and life science research. Prior to joining Ubix, Dr. Yang served as Executive Director at Syntekabio, where she led strategic partnerships and alliances in AI-based drug discovery and contributed to the company’s successful KOSDAQ IPO. She earned her PhD in Molecular, Cellular, and Developmental Biology and Genetics from the University of Minnesota and completed postdoctoral research at the National Institutes of Health (NIH) in the U.S.
About ACCESS ASIA BD Forum @ JPM 2026
ACCESS ASIA BD Forum @ JPM is scheduled to be held on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference Week.
This full-day forum will feature keynote speeches, panel discussions, corporate presentations, company showcases, and 1-on-1 partnering meetings connecting Asia’s leading biotech innovators with global pharma, investors, and strategic partners.
Conference Name: ACCESS ASIA BD Forum @ JPM 2026
Date & Venue: January 11, 2026 | InterContinental San Francisco
View more information at: https://biotochina.org/
MORE INFORMATION
Contact Us
Register as an attendee for ACCESS ASIA BD Forum @ JPM:
For more information, please contact:
Wendi Xiang | Wxiang@yafocapital.com
BioToChina.org 